Abstract Number: 352 • 2017 ACR/ARHP Annual Meeting
Psychometric Features of a New Methotrexate (MTX)-Specific Adherence Tool for Use in the Management of Patients with Rheumatoid Arthritis (RA): Preliminary Results from an Online Patient Community
Background/Purpose: F. Hoffmann-La Roche Ltd. and Mapi collaborated to develop a medication adherence measure among RA patients taking MTX—the Methotrexate Experience Questionnaire (MEQ). The MEQ…Abstract Number: 353 • 2017 ACR/ARHP Annual Meeting
Patient Experiences of Rheumatoid Arthritis Models of Care: An International Survey
Background/Purpose: Despite the global prevalence of rheumatoid arthritis (RA), there is no single model of care (MoC) and little is known about the RA patient…Abstract Number: 354 • 2017 ACR/ARHP Annual Meeting
Multidomain Functional Assessment in a Cohort of Patients with Systemic Lupus Erythematosus: A Pilot Study
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, complex disease with multiple comorbid conditions and non-disease-specific manifestations. Consequently, the impact of SLE on both physical…Abstract Number: 355 • 2017 ACR/ARHP Annual Meeting
Perceptions and Outcomes of Pregnancy and Lactation in Patients with Rheumatic Diseases
Background/Purpose: Once diagnosed with a rheumatic disease, women often defer or avoid pregnancy or lactation, fearing adverse outcomes for their offspring or for themselves. Scant…Abstract Number: 356 • 2017 ACR/ARHP Annual Meeting
Preliminary Real World Data on Switching Patterns between Etanercept, Its Recently Marketed Biosimilar Counterpart and Its Competitor Adalimumab, Using Swedish Prescription Registry
Background/Purpose: The increasing availability of biologic treatments over the past 10 years has revolutionized the management of rheumatic diseases. In April 2016, the first etanercept…Abstract Number: 357 • 2017 ACR/ARHP Annual Meeting
Determinants of Patient and Physician Disagreement on Presence of a Gout Flare
Background/Purpose: Flare is a central feature of gout and patient self-report of flare was found to be an important element in a gout flare definition…Abstract Number: 358 • 2017 ACR/ARHP Annual Meeting
Patients and Physicians Have Different Perceptions of the Relative Bother of the Symptoms and Impacts on Daily Activities in Psoriasis and Psoriatic Arthritis
Background/Purpose: Psoriasis and psoriatic arthritis arise from the same immune system response but result in different symptoms and impacts on daily activities. A patient with…Abstract Number: 359 • 2017 ACR/ARHP Annual Meeting
Nurse Telephone Education for Promoting a Treat-to-Target Approach in Recently Diagnosed Rheumatoid Arthritis Patients – a Preliminary Review
Background/Purpose: A successful Treat-to-Target approach to managing Rheumatoid Arthritis (RA) requires shared decision making with patients and healthcare providers. However patients may not have the…Abstract Number: 360 • 2017 ACR/ARHP Annual Meeting
Evaluation of the Educational Needs in Argentinian Patients with Rheumatoid Arthritis Using the SpENAT Questionnaire
Background/Purpose: The SpENAT, a Spanish version of the Educational Needs Assessment Tool, is a self-completed questionnaire that assesses educational needs (ENs) with the purpose of…Abstract Number: 361 • 2017 ACR/ARHP Annual Meeting
Multi-National Observational Patient Diary Study to Assess Disease Burden of Periodic Fever Syndromes (PFS), Including Colchicine-Resistant Familial Mediterranean Fever (crFMF), TNF-Receptor Associated Periodic Syndrome (TRAPS) and Mevalonate Kinase Deficiency (MKD)
Background/Purpose: Periodic fever syndromes (PFS) are a group of autoinflammatory disorders characterized by recurrent bouts of fever and severe localized inflammation which, if not treated,…Abstract Number: 362 • 2017 ACR/ARHP Annual Meeting
Patients’ Experiences and Attitudes about Non-Medical Switching of Biologics: Results from an Online Patient Survey
Background/Purpose: Health insurance plan designs often have benefits that result in highly prescriptive patient (pt) treatment options that can result in switching of patient’s medications…Abstract Number: 363 • 2017 ACR/ARHP Annual Meeting
Work Productivity Benefit in Patients with Rheumatoid Arthritis Initiating Etanercept in the United States
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that can progress to joint destruction, functional impairment and disability that can lead to work productivity…Abstract Number: 364 • 2017 ACR/ARHP Annual Meeting
Canakinumab First or Second Choice in Systemic Juvenile Idiopathic Arthritis – Experience from Clinical Practice
Background/Purpose: Canakinumab (CAN) has demonstrated its efficacy and safety in systemic juvenile idiopathic arthritis in clinical trials. We report on the experience with CAN in…Abstract Number: 365 • 2017 ACR/ARHP Annual Meeting
Canakinumab Treatment in Patients with Still’s Disease: A Pooled Analysis of Systemic Juvenile Idiopathic Arthritis Data By Age Groups
Background/Purpose: Still’s disease presents in pediatric and adult patients as a disease continuum with similar symptoms and pathophysiology.1,2 The objective of this analysis was to…Abstract Number: 366 • 2017 ACR/ARHP Annual Meeting
Short-Term Outcomes in Patients with Systemic-Onset Juvenile Idiopathic Arthritis Treated with Either Tocilizumab or Anakinra in a Real-World Setting in the United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) comprises 7 ILAR categories, but systemic-onset JIA (sJIA) appears to be distinct in genetic background and pathogenesis from the other…
ACR Meeting Abstracts